UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 20, 2006

                              ALFACELL CORPORATION
             (Exact name of registrant as specified in its charter)

                                     0-11088
                            (Commission File Number)

                Delaware                                   22-2369085
        (State or other jurisdiction of    (I.R.S. Employer Identification No.)
         incorporation)

               225 Belleville Avenue, Bloomfield, New Jersey 07003
             (Address of principal executive offices, with zip code)

                                 (973) 748-8082
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     [ ] Written  communications  pursuant to Rule 425 under the Securities Act
          (17 CFR 230.425)

     [ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
          (17 CFR 240.14a-12)

     [ ] Pre-commencement  communications pursuant to Rule 14d-2(b) under the
          Exchange Act (17 CFR 240.14d-2(b))

     [ ] Pre-commencement  communications pursuant to Rule 13e-4(c) under the
          Exchange Act (17 CFR 240.13e-4(c))



ITEM 8.01         OTHER EVENTS.

     On December 20, 2006,  Alfacell  Corporation (the "Company") issued a press
release  announcing  that  it  has  entered  into  an  exclusive  licensing  and
distribution  agreement with GENESIS Pharma S.A., for the  commercialization  of
its  lead  drug  candidate,   ONCONASE(R)  (ranpirnase)  for  the  treatment  of
unresectable  malignant  mesothelioma  ("UMM").  A copy of the press  release is
filed as Exhibit 99.1 hereto and incorporated herein by reference.

     On December 21, 2006, the Company issued a press release announcing that it
has filed an  application  with the U.S. Food and Drug  Administration  (FDA) to
obtain orphan  designation  for  ONCONASE(R)  for the treatment of patients with
UMM.  A copy  of  the  press  release  is  filed  as  Exhibit  99.2  hereto  and
incorporated herein by reference.

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS.

(c)   Exhibits.

99.1  Press release of Alfacell Corporation dated December 20, 2006.

99.2  Press release of Alfacell Corporation dated December 21, 2006.


                                      -2-





                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                 ALFACELL CORPORATION



Date:  December 21, 2006                         By: /s/ Robert D. Love
                                                         Robert D. Love
                                                         Chief Financial Officer

                                      -3-